Evidence map›Paper›PMID 33553672›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2021

Soichiro Sue, Tomohiko Sasaki, Hiroaki Kaneko, Kuniyasu Irie, Masaaki Kondo, Shin Maeda

Open access · goldAbstract read
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Frontiers in cellular and infection microbiology · 2022
    Trial
  4. Third-Line and Later Susceptibility-GuidedJournal of clinical medicine · 2026
    Article
  5. Differences and trends in worldwide clinical guidelines forTranslational gastroenterology and hepatology · 2026
    Review
  6. A Review on the Progress and Strategies ofGastroenterology research and practice · 2026
    Review
  7. Review
  8. Single-Arm, Prospective, Interventional Study ofJournal of clinical medicine · 2024
    Article
  9. Comparison of metronidazoleJGH open : an open access journal of gastroenterology and hepatology · 2024
    Article
  10. Article
  11. Treatment ofAntibiotics (Basel, Switzerland) · 2023
    Review
  12. Real-world outcomes associated with vonoprazan-basedTherapeutic advances in gastroenterology · 2023
    Article
  13. Vonoprazan and high-dose amoxicillin dual therapy forJGH open : an open access journal of gastroenterology and hepatology · 2023
    Article
  14. Article
  15. Treatment ofWorld journal of gastroenterology · 2021
    Review
  16. Sitafloxacin for Third-LineJournal of clinical medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Soichiro SueDepartment of Gastroenterology Yokohama City University Graduate School of Medicine Yokohama Japan.
Tomohiko SasakiDepartment of Gastroenterology Yokohama City University Graduate School of Medicine Yokohama Japan.
Hiroaki KanekoDepartment of Gastroenterology Yokohama City University Graduate School of Medicine Yokohama Japan.
Kuniyasu IrieDepartment of Gastroenterology Yokohama City University Graduate School of Medicine Yokohama Japan.
Masaaki KondoDepartment of Gastroenterology Yokohama City University Graduate School of Medicine Yokohama Japan.
Shin MaedaDepartment of Gastroenterology Yokohama City University Graduate School of Medicine Yokohama Japan.ORCID https://orcid.org/0000-0002-0246-1594
Yokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimTo assess the efficacy and safety of 7-day

methodsThis was a registered prospective intervention study. Patients with penicillin allergy who were diagnosed with

resultsThe eradication rate of 7-day VPZ-MNZ-SFTX therapy was 88.2% (95% confidence interval: 63.6-98.5%;

conclusionRescue

Indexed as

Helicobacter pylorihypersensitivitymetronidazolesitafloxacinvonoprazan

Identifiers

PMID33553672
PMCPMC7857288
OpenAlexW3123967122

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.